A Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With Schizophrenia

This 6-week, multicenter, randomized withdrawal, placebo-controlled trial sought to determine whether symptoms of physical dependence occur after abrupt cessation of pomaglumetad methionil (LY2140023 monohydrate), a metabotropic glutamate 2/3 receptor agonist, in patients with schizophrenia. Eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauffer, Virginia L., Baygani, Simin K., Kinon, Bruce J., Krikke-Workel, Judith O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165473/
https://www.ncbi.nlm.nih.gov/pubmed/25006819
http://dx.doi.org/10.1097/JCP.0000000000000187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165473/
https://www.ncbi.nlm.nih.gov/pubmed/25006819
http://dx.doi.org/10.1097/JCP.0000000000000187

Ejemplares similares